Title: MELDONIUM SALTS, METHOD OF THEIR PREPARATION AND PHARMACEUTICAL COMPOSITION ON THEIR BASIS

Abstract: New salts of Meldonium, the method of their preparation, and pharmaceutical formulation on their basis have been described. The general formula of these salts is X-(CH3)3N+NHCH2CH2COOH where X- is an acid anion selected from the group of pharmaceutically acceptable acids. Practically non-hygroscopic and/or increased thermal stability and/or lasting action Meldonium hydrogen salts of fumaric acid, phosphoric acid, oxalic acid, maleic acid, and pamoic acid as well as Meldonium orotate and galactarate are especially suitable. Novel pharmaceutical formulations containing non-hygroscopic and/or increased thermal stability and/or lasting action 3-(2,2,2-trimethylhydrazinium) propionate salts for oral, parenteral, rectal and transdermal introduction are concurrently described.
DESCRIPTION

Meldonium Salts, Method of Their Preparation and Pharmaceutical Compositions on Their Basis.

TECHNICAL FIELD

The present invention relates to 3-(2,2,2-trimethylhydrazinium)propionate salts of the general formula X'(CH₃)₃N₃NHCH₂CH₂COOH where X’ is an acid anion selected from the group of acid phosphate, acid fumarate, acid oxalate, acid maleate and/or acid pamoate, orotate, galactarate, sulfate, dichloroacetate, acid galactarate, fumarate, taurate, maleate, acid aspartate, creatinate, acid sulfate, magnesium succinate, acid citrate, citrate, succinate, acid succinate, adipinate, acid tartrate and lactate, which distinguish from 3-(2,2,2-trimethylhydrazinium) propionate dihydrate by low hygroscopicity and/or increased thermal stability and/or lasting action. This invention relates also to the method of such salt preparation and to pharmaceutical formulations containing the said salts.

BACKGROUND OF THE INVENTION

3-(2,2,2-Trimethylhydrazinium) propionate is disclosed in US Patent No.4481218.


Due to these properties, Meldonium (registered with the trade mark of „MILDRONĀTS” , “MILDRONATE”, “МИЛДРОНАТ”) is extensively applied in medicine as an anti-ischemic un stress-protective drug in treating various cardiovascular diseases and other pathologies involving tissue ischemia (R.S.Karpov, O.A.Koshelskaya, A.V.Vrublevsky, A.A.Sokolov, A.T.Teplyakov, I.Skarda, V.Dzerve, D.Klintsare, A.Vitols, I.Kalvinsh, L.Matveyeva, D.Urbane. Clinical

However, Meldonium as dihydrate has essential drawbacks, the first of which consists in its rather high hygroscopicity. Already after 24 hours maintenance at 100% air humidity, Meldonium mass is increased by 10% because of water absorption, the substance being transformed into a syrup.

Other essential drawback of Meldonium is caused by the half-elimination period equalling 4-10 hours for humans while this drug must be used 2-4 times daily in the clinic (V. Dzērve. Mildronāts. PAS “Grindeks”, 1999, p.1), though it is longer in trials on rats (K. Yoshiue, Y. Yamomoto, K. Yoshida, M. Saeki, Y. Minami, Y. Esumi, Y. Kawaguchi. Pharmacokinetics and biological fate of 3-(2,2,2-trimethylhydrazinium)propionate (MET-88), a novel cardioprotective agent, in rats. Drug Metabolism and Disposition, vol.28, No6, 687-694).

As Meldonium dihydrate is unsuitable for single daily oral introduction, it was one of the aims of the present invention to find other pharmacologically acceptable Meldonium forms which would be applicable for single daily use. It is generally known that amino acid betaine salts usually have good solubility in water. If pharmacologically acceptable acids are selected, resorption and elimination pharmacokinetics and biological activity of these salts normally does not much differ from the parameters of the initial compound.

Besides, Meldonium is not very stable: while heated, it fast loses the water of the crystal hydrate. In turn, the anhydrous form of Meldonium is unstable and extremely hygroscopic. In such form, this compound soon becomes coloured and gets a specific annoying odour. Thus, the hygroscopicity and thermal non-stability of Meldonium dihydrate are significant disadvantages restricting the possibilities of preparing different oral and external drug dosage forms from this compound. Furthermore, Meldonium dihydrate is actively dehydrated at temperatures so low as 40-45°C. This means that sure storage of Meldonium dosage forms containing crystal hydrate is rather embarrassing in countries with hot climate.

Because Meldonium dihydrate is not readily applicable for producing drug oral dosage forms, it was a further object of this invention to find other pharmacologically acceptable salts of Meldonium which would lack hygroscopicity or/and, be thermally stable and could be stored in any climatic zone for a long time.
DETAILED DESCRIPTION OF THE INVENTION

For most Meldonium salts, their pharmacokinetic properties practically do not differ from those described for Meldonium. Therefore the use of these salts for preparing pharmaceutical compositions seemingly have no advantage as compared to Meldonium.

To our surprise, we suddenly found that Meldonium salts of some pharmaceutically acceptable polybasic acids are an exception in this respect; although readily soluble in water, they essentially differ from Meldonium by their pharmacokinetic and pharmacodynamic properties.

It was an astonishing discovery since no theoretical argument exists why Meldonium salts, which are easily soluble in water should have resorption and elimination speed different from that of Meldonium.

Nevertheless, we succeeded in finding among the above salts some specific Meldonium salts with appropriate pharmacokinetics and pharmacodynamics allowing their single daily use; they are: $X'(CH_3)_2N^+NHCH_2CH_2COOH$ where $X'$ is the anion of acids is selected from the group of mono-substituted fumaric acid, mono-substituted phosphoric acid, mono-substituted oxalic acid, mono-substituted maleic acid un mono- and/or di-substituted galactaric, pamoic acids and orotic acid.

It is common knowledge that betaines of amino acids are commonly relatively stable substances. It is well known that these compounds are readily soluble in water and the biological activity of their pharmaco logically acceptable salts usually does not differ from that of the initial compound.

However, Meldonium and monobasic, dibasic as well as tribasic pharmaceutically acceptable acid salts have equal or even higher hygroscopicity than Meldonium itself. Moreover, many of them cannot be prepared in crystalline form at all because they form syrups containing variable quantity of water.

The salts of both strong and weak acids, viz. Meldonium sulfate, hydrogen chloride, acetate, lactate, citrate as well as salts of many other pharmaceutically acceptable acids are hygroscopic. Consequently, using these salts for preparation of pharmaceutical compositions for oral use is deemed lacking preference to that of Meldonium.

We noticed completely unexpectedly that Meldonium salts of some pharmaceutically acceptable polybasic acids are exceptional in this regard; they
proved to be practically non-hygroscopic though easily soluble in water. We observed that these compounds are also very stable while maintained at both room temperature and temperatures up to at least 50 centigrade over a long period of time. Similarly we gained the unanticipated result that such specific monobasic acid as orotic acid forms a non-hygroscopic Meldonium salt, too. All of the claimed salts proved more stable thermally than Meldonium.

Orally administered Meldonium is easily bioavailable also from these salts, therefore these salts are much more suitable for preparing various drug dosage forms than the hygroscopic and thermally unstable Meldonium. It was an astounding discovery because no theoretical underpinning suggests any difference of Meldonium orotate or polybasic acid salts, which are also readily soluble in water, from other salts as to hygroscopicity.

Since they are not hygroscopic and/or have increased thermal stability, these salts can be easily handled and are favourably suitable for manufacturing solid administration forms. Their aqueous solutions are less acid than those of the corresponding chlorides: consequently these salts are also more suitable for manufacturing injectable administration forms.

The following non-limiting examples illustrate the preparation of salts according to the present invention.

EXAMPLE 1

The following methods may be applied for the preparation of these salts. Meldonium is dissolved in water or other appropriate solvent, an equimolar quantity of a polybasic acid selected from the group of fumaric acid, phosphoric acid, aspartic acid, citric acid, lactic acid, maleic acid, oxalic acid, or orotic acid (the latter is taken in semi-molar quantity) is added, and the mixture is stirred at temperature from 20 to 50°C till the corresponding salt is formed. At the second technological stage, Meldonium salts are evaporated to dryness if necessary. At the third technological stage, in case of need the obtained salts are recrystallised from a suitable solvent.

EXAMPLE 2

The said salts can also be prepared from the corresponding salts of Meldonium production intermediates, viz. methyl- or ethyl-esters of 3(2,2,2-trimethylhydrazinium) propionate, the latter being heated together with the corresponding acids in aqueous or aqueous-alcoholic solutions, and subsequent
treatment, eduction and purification being performed by analogy with the first method of preparation.

EXAMPLE 3

Method of salt preparation from meldonium dihydrate. Meldonium and the corresponding acid are dissolved in a small quantity of water at 40-50°C under stirring. The obtained solution is evaporated in vacuum at 40-50°C. Acetone or acetonitrile is added to the formed mass (what predominantly is viscous syrup), and the mixture is grated. The precipitated crystalline mass is stirred in acetone or acetonitrile during several hours, filtered off, washed with acetone or acetonitrile, dried in vacuum at room temperature.

Sample hygroscopicity was tested by H₂O content determination before the test and after 24 hours maintenance at 100% humidity (keeping in a closed vessel over water). On such conditions, Meldonium absorbs 10% water (as to mass increase) during 24 hours. Water content was determined by titration by Fischer’s method; in cases of syrup formation water content is determined by sample mass increase.

The claimed invention is illustrated by, but not restricted to the following examples of salts obtained by the above method:

EXAMPLE 4

Meldonium orotate (1:1). Mp. 211-214°C. ¹H NMR spectrum (D₂O), δ, ppm: 2.56 (2H, t, CH₂COO⁻); 3.29 (2H, t, CH₂N); 3.35 (9H, s, Me₃N⁺); 6.18 (1H, s, -CH⁻). Found, %: C 43.78; H 6.01; N 18.48. Calculated, %: C 43.71; H 6.00; N 18.53. Initially H₂O content in the sample was 0.3919%; during 24 hours at 100% humidity it remains unchanged.

EXAMPLE 5

Meldonium phosphate (1:1). Mp. 158-160°C. ¹H NMR spectrum (D₂O), δ, ppm: 2.60 (2H, t, CH₂COO⁻); 3.31 (2H, t, CH₂N); 3.35 (9H, s, Me₃N⁺). Found, %: C 29.64; H 7.05; N 11.33 Calculated, %: C 29.51; H 7.02; N 11.47. Initially H₂O content in the sample was 0.0762%; during 24 hours at 100% humidity it remains unchanged.

EXAMPLE 6

Meldonium fumarate (1:1). Mp. 140-142°C. ¹H NMR spectrum, δ, ppm: 2.57 (2H, t, CH₂); 3.29 (2H, t, CH₂); 3.35 (9H, s, Me₃N⁺); 6.72 (2H, s, -CH=CH⁻). Found, %: C 45.46; H 6.94; N 10.72. Calculated, %: C 45.80; H 6.92; N 10.68. Initially H₂O
content in the sample was 0.18%; during 24 hours at 100% humidity it remains unchanged.

EXAMPLE 7
Meldonium oxalate (1:1). Mp. 123-125°C. $^1$H NMR spectrum (D$_2$O), δ, ppm: 2.61 (2H, t, CH$_2$COO$^-$); 3.30 (2H, t, CH$_2$N); 3.35 (9H, s, Me$_3$N$^+$). Found, %: C 40.86; H 6.82; N 11.78. Calculated, %: C 40.68; H 6.83; N 11.86. Initially H$_2$O content in the sample was 0.1661%; after 24 hours maintenance at 100% humidity it was 3.1211%.

EXAMPLE 8
Meldonium maleate (1:1). Mp. 98-100°C. $^1$H NMR spectrum (D$_2$O), δ, ppm: 2.60 (2H, t, CH$_2$COO$^-$); 3.31 (2H, t, NCH$_2$); 3.35 (9H, s, Me$_3$N$^+$); 6.35 (2H, s, –CH=CH–). Found, %: C 45.93; H 6.95; N 10.65. Computational, %: C 45.80; H 6.92; N 10.68. Initially H$_2$O content in the sample was 0.387%; after 24 hours maintenance at 100% humidity it was 4.6844%.

EXAMPLE 9
Meldonium mucate (galactarate; 2:1; ×H$_2$O). Mp. 152-154°C. $^1$H NMR spectrum (D$_2$O), δ, ppm: 2.46 (4H, t, 2 × CH$_2$COO$^-$); 3.26 (4H, t, 2 × NCH$_2$); 3.35 (18H, s, 2 × Me$_3$N$^+$); 3.98 un 4.31 – two singlets of low intensity, protons of mucic acid. Found, %: C 42.13; H 7.58; N 10.77. Calculated, %: C 41.53; H 7.75; N 10.76. Initially H$_2$O content in the sample was 3.0414%; after 24 hours maintenance at 100% humidity it was 7.6830%.

EXAMPLE 10
Meldonium pamoate (1:1; × H$_2$O). Meldonium (5.46 g, 30 mmol) and pamoic acid (5.82 g, 15 mmol) are mixed with water and acetone (15 + 15 ml), the formed suspension is evaporated, 30-40 ml toluene is added to the residual viscous mass, it is grated, and evaporation is repeated. If the residue is insufficiently dry, treatment with toluene is repeated. Mp. 128-133°C (decomp.). $^1$H NMR spectrum (DMSO-d$_6$), δ, ppm: 2.41 (2H, t, CH$_2$COO$^-$); 3.14 (2H, t, CH$_2$N); 3.25 (9H, s, Me$_3$N$^+$); 4.75 (2H, s, –CH$_2$–pam.); 7.12 (2H, t, H$_{arom}$); 7.26 (2H, td, H$_{arom}$); 7.77 (2H, d, H$_{arom}$); 8.18 (2H, d, H$_{arom}$); 8.35 (2H, s, H$_{arom}$). Found, %: C 62.90; H 5.83; N 4.98. Calculated, %: C 63.07; H 5.84; N 5.07. Initially H$_2$O content in the sample was 1.71%; after 24 hours maintenance at 100% humidity sample mass increased by 9% due to absorbed water.

EXAMPLE 11
Meldonium sulfate (2:1). T_m 80-182°C (decomp.). $^1$H NMR spectrum (D_2O), δ, ppm: 2.60 (4H, t, 2 × CH_2COO$^-$); 3.30 (4H, t, 2 × CH_2N); 3.35 (18H, s, 2 × Me_3N$^+$). Found, %: C 37.08; H 7.73; N 14.29; S 8.20. Calculated, %: C 36.91; H 7.74; N 14.35; S 8.21. Initially H_2O content in the sample was 0.313%; after 24 hours maintenance at 100% humidity sample mass increased by 11.8% due to absorbed water.

EXAMPLE 12

Meldonium dichloroacetate (1:1). Mp. 86-88°C. $^1$H NMR spectrum (D_2O), δ, ppm: 2.61 (2H, t, CH_2COO$^-$); 3.31 (2H, t, CH_2N); 3.35 (9H, s, Me_3N$^+$); 6.05 (1H, s, CHCl_2). Found, %: C 35.13; H 5.85; N 10.10. Calculated, %: C 34.92; H 5.86; N 10.18. Initially H_2O content in the sample was 1.17%; after 24 hours maintenance at 100% humidity sample mass increased by 12% due to absorbed water.

EXAMPLE 13

Meldonium mucate (galactarate; 1:1). Mp. 152-154°C. $^1$H NMR spectrum (D_2O), δ, ppm: 2.47 (2H, t, CH_2COO$^-$); 3.26 (2H, t, CH_2N); 3.35 (9H, s, Me_3N$^+$); 3.71 and 3.98 – two singlets of low intensity, protons of the slightly soluble mucic acid. Found, %: C 40.22; H 6.75; N 7.75%. Calculated, %: C 40.22; H 6.79; N 7.86. Initially H_2O content in the sample was 1.98%; after 24 hours maintenance at 100% humidity it was 12.8%.

EXAMPLE 14

Meldonium fumarate (2:1). Mp. 156-158°C. $^1$H NMR spectrum (D_2O), δ, ppm: 2.53 (4H, t, 2 × CH_2(meld)); 3.29 (4H, t, 2 × CH_2(meld)); 3.35 (18H, s, 2 × Me_3N$^+$); 6.65 (2H, s, CH=CH–(fumar)). Found, %: C 46.68; H 7.91; N 13.69. Calculated, %: C 47.05; H 7.90; N 13.72. Initially H_2O content in the sample was 1.5136%; after 24 hours maintenance at 100% humidity it was 13.4707%.

EXAMPLE 15

Meldonium 2-aminoethane sulfonate (taurate; 1:1; ×1.5H_2O). Mp. 190-193°C (with decomp.). $^1$H NMR spectrum (D_2O), δ, ppm: 2.38 (2H, t, CH_2COO$^-$); 3.18-3.30 (4H, m, NCH_2(meld) + CH_2(taur.)); 3.34 (9H, s, Me_3N$^+$); 3.42 (2H, t, CH_2(taur.)). Found, %: C 32.40; H 8.16; N 13.98; S 10.60. Calculated, %: C 32.21; H 8.11; N 14.08; S 10.75. Initially H_2O content in the sample was 9.4824%; after 24 hours maintenance at 100% humidity it was 17.0854%. 
EXAMPLE 16

Meldonium maleate (2:1). Mp. 104-106°C. \(^1\)H NMR spectrum (D\(_2\)O), \(\delta\), ppm: 2.54 (4H, t, CH\(_2\)COO\(^-\)); 3.30 (4H, t, CH\(_2\)N); 3.35 (18H, s, Me\(_3\)N\(^+\)); 6.42 (2H, s, \(-CH=CH-\)). Found, %: C 46.59; H 7.88; N 13.50. Calculated: C 47.05; H 7.90; N 13.72. Initially H\(_2\)O content in the sample was 1.3595%; after 24 hours maintenance at 100% humidity sample mass increased by 18% due to absorbed water.

EXAMPLE 17

Meldonium L-(+)-aspartate (1:1; \(\times\)2H\(_2\)O). Mp. 146-148°C. \(^1\)H NMR spectrum (D\(_2\)O), \(\delta\), ppm: 2.49 (2H, t, CH\(_2\)COO\(^-\)); 2.70-2.99 (2H, m, CH\(_2\)(subp.)) 3.27 (2H, t, CH\(_2\)N); 3.35 (9H, s, Me\(_3\)N\(^+\)); 3.95 (1H, dd, CHNH\(_2\)). Found, %: C 37.71; H 7.85; N 13.03. Calculated, %: C 38.09; H 7.99; N 13.33. Initially H\(_2\)O content in the sample was 12.5%; after 24 hours maintenance at 100% humidity sample mass increased by 18% due to absorbed water.

EXAMPLE 18

Meldonium creatinate (1:1; \(\times\)3H\(_2\)O). Mp. 227-228°C (decomp.). \(^1\)H NMR spectrum (D\(_2\)O), \(\delta\), ppm: 2.38 (2H, t, CH\(_2\)COO\(^-\)); 3.03 (3H, s, NMe\(_2\)(creatine)); 3.22 (2H, t, CH\(_2\)N); 3.35 (9H, s, Me\(_3\)N\(^+\)); 3.92 (2H, s, NCH\(_2\)(creatine)). Initially H\(_2\)O content in the sample was 15.8%; after 24 hours maintenance at 100% humidity sample mass increased by 18% due to absorbed water.

EXAMPLE 19

Meldonium sulfate (1:1). T\(_m\) 98-100°C. \(^1\)H NMR spectrum (D\(_2\)O), \(\delta\), ppm: 2.62 (2H, t, CH\(_2\)COO\(^-\)); 3.31 (2H, t, CH\(_2\)N); 3.35 (9H, s, Me\(_3\)N\(^+\)). Found, %: C 29.23; H 6.57; N 11.17; S 13.10. Calculated: C 29.50; H 6.60; N 11.47; S 13.13. Initially H\(_2\)O content in the sample was 1.4189%; after 24 hours maintenance at 100% humidity sample mass increased by 20% due to absorbed water.

EXAMPLE 20

Meldonium magnesium succinate (1:1:1; \(\times\)2H\(_2\)O). (see Meldonium-magnesium tartrate). Mp. 135-140°C (decomp.). \(^1\)H NMR spectrum (D\(_2\)O), \(\delta\), ppm: 2.39 (2H, t, CH\(_2\)COO\(^-\)); 2.46 (4H, s, \(-CH_2-CH_2-(succin.ac.)); 3.22 (2H, t, CH\(_2\)N); 3.35 (9H, s, Me\(_3\)N\(^+\)). Found, %: C 36.66; H 7.28; N 8.37. Calculated: C 37.23; H 6.87; N 8.68. Initially H\(_2\)O content in the sample was 10.1215%; after 24 hours maintenance at 100% humidity sample mass increased by 20% due to absorbed water.

EXAMPLE 21
Meldonium magnesium citrate (1:1:1; ×2H₂O) (see Meldonium-magnesium tartrate). Mp. 195-200°C (decomp.). ¹H NMR spectrum (D₂O), δ, ppm: 2.48 (2H, t, CH₂COO⁻); 2.75 (4H, dd, 2×CH₂(citr.)); 3.26 (2H, t, CH₂N); 3.34 (9H, s, Me₃N⁺). Found, %: C 36.58; H 6.09; N 6.96. Calculated: C 36.34; H 6.10; N 7.06. Initially H₂O content in the sample was 9.45%; after 24 hours maintenance at 100% humidity the sample diffused.

EXAMPLE 22
Meldonium citrate (1:1). Mp: 90-95°C (decomp.). ¹H NMR spectrum (D₂O), δ, ppm: 2.56 (2H, t, CH₂COO⁻); 2.85 (4H, dd, 2×CH₂(citr.)); 3.28 (2H, t, CH₂N); 3.35 (9H, s, Me₃N⁺).

EXAMPLE 23
Meldonium citrate (2:1). Mp: 101-107°C (decomp.). ¹H NMR spectrum (D₂O), δ, ppm: 2.51 (4H, t, 2×CH₂COO⁻); 2.81 (4H, dd, 2×CH₂(citr.)); 3.26 (4H, t, 2×CH₂N); 3.35 (18H, s, 2×Me₃N⁺).

EXAMPLE 24
Meldonium succinate (1:1). Mp: 95-100°C (decomp.). ¹H NMR spectrum (D₂O), δ, ppm: 2.51 (2H, t, CH₂(meldon.)); 2.60 (4H, s, –CH₂–CH₂–(succ.in.ac.)); 3.27 (2H, t, CH₂(meldon.)); 3.35 (9H, s, Me₃N⁺).

EXAMPLE 25
Meldonium succinate (2:1). Mp: 103-107°C (decomp.). ¹H NMR spectrum (D₂O), δ, ppm: 2.47 (4H, t, 2×CH₂(meldon.)); 2.59 (4H, s, –CH₂–CH₂–(succ.in.ac.)); 3.29 (4H, t, 2×CH₂(meldon.)); 3.35 (18H, s, 2×Me₃N⁺).

EXAMPLE 26
Meldonium adipinate (2:1). Mp: 110-114°C (decomp.). ¹H NMR spectrum (D₂O), δ, ppm: 1.55-1.70 (4H, m, 2×CH₂(adip.)); 2.28-2.39 (4H, m, 2×CH₂(adip.)); 2.45 (4H, t, 2×CH₂(meldon.)); 3.24 (4H, t, 2×CH₂(meldon.)); 3.34 (18H, s, 2×Me₃N⁺).

EXAMPLE 27
Meldonium tartrate (1:1). Mp: 100-107°C (decomp.). ¹H NMR spectrum (D₂O), δ, ppm: 2.57 (2H, t, CH₂COO⁻); 3.29 (2H, t, CH₂(meldon.)); 3.35 (9H, s, Me₃N⁺); 4.55 (2H, s, CH₃(tart.ac.)).
Meldonium lactate (1:1). Mp. 110-114°C (decomp.).\(^1\)H NMR spectrum (D\(_2\)O), \(\delta\), ppm: 1.33-1.48 (3H, m, Me\(_{\text{lact.ac.}}\)); 2.50 (2H, t, CH\(_2\text{COO}^-\)); 3.26 (2H, t, CH\(_2\text{mildr.})\); 3.35 (9H, s, Me\(_3\text{N}^+\)); 4.21 (1H, q, CH\(_{\text{lact.ac.}}\)).

This invention relates also to pharmaceutical formulations containing at least one of the Meldonium salts described herein as pharmaceutical active and pharmaceutically acceptable solid or liquid excipients used in drug dosage form production. Solid formulations suitable for producing dosage forms of oral introduction as well as syrups and solutions containing the claimed salts and excipients are preferable.

In case when the active substance(s) is (are) inserted into tablets, caplets, pills, granules, powders, or capsules, they shall contain a Meldonium salt from 0,5 to 5 gr. per tablet, caplet, pill, capsule or one portion of powder or granules.

The following non-limiting examples illustrate the pharmaceutical formulation of salts for solid formulation

**EXAMPLE 29** Formulation for manufacturing tablets:

<p>| | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>A Meldonium salt</td>
<td>500 mg</td>
</tr>
<tr>
<td>according to the invention</td>
<td></td>
</tr>
<tr>
<td>Starch</td>
<td>20 mg</td>
</tr>
<tr>
<td>Talc</td>
<td>10 mg</td>
</tr>
<tr>
<td>Ca-stearate</td>
<td>1 mg</td>
</tr>
<tr>
<td>Total</td>
<td>531 mg</td>
</tr>
</tbody>
</table>

The following non-limiting examples illustrate composition suitable for producing capsules is the following:

**EXAMPLE 30**

<p>| | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>A Meldonium salt</td>
<td>500 mg</td>
</tr>
<tr>
<td>according to the invention</td>
<td></td>
</tr>
<tr>
<td>Starch</td>
<td>66mg</td>
</tr>
<tr>
<td>Talc</td>
<td>26 mg</td>
</tr>
<tr>
<td>Ca-stearate</td>
<td>3 mg</td>
</tr>
<tr>
<td>Total</td>
<td>602 mg</td>
</tr>
</tbody>
</table>
In case if the active(s) are introduced by injections or orally by means of drops, a syrup or beverage, the pharmaceutical formulation shall contain a Meldonium salt according to this invention in a ratio of 0.5 to 60% by weight and a pharmaceutically admissible solvent, e.g. distilled water, an isotonic, glucose or buffer solution or mixtures of them.

The following non-limiting examples illustrate the pharmaceutical formulation of salts for injectable administration or/and orally administration:

EXAMPLE 31

Injection formulation:
A Meldonium salt 500 mg
according to the invention
Water for injections 5ml

EXAMPLE 32

A syrup formulation:
A Meldonium salt 25.00 mg
according to the invention
Methyl-p-hydroxybenzoate 0.20-0.60 g
Propyl-p-hydroxybenzoate 0.01-0.1 g
Propylene glycol 6.15-8.30g
Sorbit 120.00-150.50 g
Glycerine 10.00-15.00 g
Purified water 108ml
Total 250ml

In case of trans-dermal application of the active(s), it's (their) content in an cream, gel, solution, ointment or plaster shall be 0.5-40% by weight.

The following non-limiting examples illustrate the pharmaceutical formulation of salts for trans-dermal (local/topical) administration:

EXAMPLE 33

Gel formulation:
A Meldonium salt 10,00%
<table>
<thead>
<tr>
<th>Ingredient</th>
<th>Quantity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sodium starch glycollate</td>
<td>4.00</td>
</tr>
<tr>
<td>type C,</td>
<td></td>
</tr>
<tr>
<td>Propylene glycol</td>
<td>2.00</td>
</tr>
<tr>
<td>Fumaric acid</td>
<td>0.40</td>
</tr>
<tr>
<td>Purified water</td>
<td>83.40</td>
</tr>
</tbody>
</table>

In the case the salt are administered rectally their content in a suppository or microenema accounts for 0.5 to 40% by weight.
13
CLAIMS

1. Meldonium salts of the general formula: $X'(CH_3)_3NHCH_2CH_2COOH$
   wherein $X'$ is an anion selected from the group consisting of hydrogen
   phosphate, hydrogen fumarate, hydrogen oxalate, hydrogen maleate, hydrogen
   pamoate, orotate, galactarate, sulfate, dichloroacetate, hydrogen galactarate,
   fumarate, taurate, maleate, hydrogen aspartate, creatinate, hydrogen sulfate,
   magnesium succinate, hydrogen citrate, citrate, succinate, hydrogen succinate,
   adipinate, hydrogen tartrate and lactate anions

2. A salt of claim 1 is meldonium hydrogen phosphate

3. A salt of claim 1 is meldonium fumarate

4. A salt of claim 1 is meldonium hydrogen fumarate

5. A salt of claim 1 is meldonium hydrogen oxalate

6. A salt of claim 1 is meldonium maleate

7. A salt of claim 1 is meldonium hydrogen maleate

8. A salt of claim 1 is meldonium hydrogen pamoate

9. A salt of claim 1 is meldonium orotate

10. A salt of claim 1 is meldonium dichloroacetate

11. A salt of claim 1 is meldonium galactarate

12. A salt of claim 1 is meldonium hydrogen galactarate

13. A salt of claim 1 is meldonium hydrogen aspartate

14. A salt of claim 1 is meldonium creatinate

15. A salt of claim 1 is meldonium sulphate

16. A salt of claim 1 is meldonium hydrogen sulphate

17. A salt of claim 1 is meldonium citrate

18. A salt of claim 1 is meldonium hydrogen citrate

19. A salt of claim 1 is meldonium succinate

20. A salt of claim 1 is meldonium hydrogen succinate

21. A salt of claim 1 is meldonium magnesium succinate
22. A salt of claim 1 is meldonium adipinate

23. A salt of claim 1 is meldonium taurate

24. A salt of claim 1 is meldonium hydrogen tartrate

25. A salt of claim 1 is meldonium lactate

26. The pharmaceutical composition comprising one of salts from claim 1, which is intended for oral or sublingual administration and is in the form of tablets, with or without coating, capsules, caplets, dragees, granules, powder or solution, which contain 0.01-0.5 g of the active system in every tablet, capsule, dragee, granule or powder dose, or also as a 0.5-40% solution or syrup for oral administration.

27. The pharmaceutical composition according to claim 26, wherein the pharmaceutically acceptable carrier is selected from the group consisting of one or more of the following: stearic acid and its salts, lactose, glucose, saccharose, starch, talc, vegetable oils, polyethylene glycols, microcrystalline cellulose, aerosil, aromatizers, flavoring agents, colorants, ethyl alcohol and water.

28. The pharmaceutical composition according to claim 1, which is intended for parenteral administration and is in a solution for injection, which contains 0.5-40% by weight of the active system and a pharmaceutically acceptable solvent.

29. The pharmaceutical composition according to claim 28, wherein the pharmaceutically acceptable solvent is selected from the group consisting of one or more of the following: distilled water, isotonic solution, buffer solution and glucose solution.

30. The pharmaceutical composition according to claim 1, which is intended for transcutaneous administration of the active system in the form of an ointment, cream, gel, solution or plaster, which contains 0.5-40% by weight of the active system, and a pharmaceutically acceptable carrier.

31. The pharmaceutical composition according to claim 30, wherein the pharmaceutically acceptable carrier is selected from the group consisting of one or more of the following: water, polyethylene glycols 400, 1500 and 4000, vegetable oils, fats, glycerine, preservatives, emulsifiers, stabilizers, porous polymer material, dimethylsulphoxide, alcohol and water.

32. The pharmaceutical composition according to claim 1, which is intended for rectal administration of the active system in the form of suppositories or microenema, which contains 0.5-40% by weight of the active system and a pharmaceutically acceptable carrier.
33. The pharmaceutical composition according to claim 32, wherein the pharmaceutically acceptable carrier is selected from the group consisting of one or more of the following: water, polyethylene glycols 400, 1500 and 4000, vegetable oils, fats, glycerine, preservatives, emulsifiers and stabilizers.

34. Use of Meldonium salt of the general formula: X'(CH₃)₂N⁻NHCH₂CH₂COOH wherein X' is an anion selected from the group consisting of mono-substituted fumaric acid, mono-substituted phosphoric acid, mono-substituted oxalic acid, mono-substituted maleic acid un mono- and/or di-substituted galactaric, pamoic acids and orotic acid, for the manufacture a pharmaceutical composition for the 1 per day administration.

35. A process for producing of any of Meldonium salts of claim 1 of general formula: X'(CH₃)₂N⁻NHCH₂CH₂COOH wherein X' is an anion selected from the group consisting of hydrogen phosphate, hydrogen fumarate, hydrogen oxalate, hydrogen maleate, hydrogen pamoate, orotate, galactarate, sulfate, dichloroacetate, hydrogen galactarate, fumarate, taurate, maleate, hydrogen aspartate, creatinate, hydrogen sulfate, magnesium succinate, hydrogen citrate, citrate, succinate, hydrogen succinate, adipinate, hydrogen tartrate and lactate anions; and
(a) dissolving in per se known manner Meldonium in water or other appropriate solvent, an equimolar quantity of a polybasic acid selected from the group of fumaric acid, phosphoric acid, aspartic acid, citric acid, lactic acid, maleic acid, oxalic acid, or orotic acid (the latter is taken in semi-molar quantity) is adding; and
(b) the mixture is stirring at temperature from 20 to 50°C till the corresponding salt is formed; and
(c) Meldonium salt is evaporating to dryness if necessary; and
(d) in case of need the obtained salt recrystallising from a suitable solvent.
INTERNATIONAL SEARCH REPORT

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C07C109/02 C07C53/00 A61K31/205

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07C A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, CHEM ABS Data, BEILSTEIN Data, WPI Data, PAJ

C. DOCUMENTS CONSIDERED TO BE RELEVANT

<table>
<thead>
<tr>
<th>Category</th>
<th>Citation of document, with indication, where appropriate, of the relevant passages</th>
<th>Relevant to claim No.</th>
</tr>
</thead>
<tbody>
<tr>
<td>X</td>
<td>WO 97/06795 A (KALVINSH IVARS ; VEVERIS MARIS (LV)) 27 February 1997 (1997-02-27) the whole document</td>
<td>1-35</td>
</tr>
<tr>
<td>X</td>
<td>US 4 481 218 A (ASTAPENOK ELENA B ET AL) 6 November 1984 (1984-11-06) the whole document</td>
<td>1-35</td>
</tr>
</tbody>
</table>

X Further documents are listed in the continuation of box C.

X Patent family members are listed in annex.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"I" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"D" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"O" document of the same patent family

Date of the actual completion of the international search: 28 September 2004

Date of mailing of the international search report: 13/12/2004

Name and mailing address of the ISA:

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-0300, Telex 31 651 epo nl
Fax (+31-70) 340-3016

Authorized officer: Lorenzo Varela, M.J.
<table>
<thead>
<tr>
<th>Category</th>
<th>Citation of document, with indication, where appropriate, of the relevant passages</th>
<th>Relevant to claim No.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patent document cited in search report</td>
<td>Publication date</td>
<td>Patent family member(s)</td>
</tr>
<tr>
<td>--------------------------------------</td>
<td>-----------------</td>
<td>--------------------------</td>
</tr>
<tr>
<td></td>
<td></td>
<td>CH 674360 A5</td>
</tr>
<tr>
<td></td>
<td></td>
<td>DE 3810264 A1</td>
</tr>
<tr>
<td></td>
<td></td>
<td>FR 2612922 A1</td>
</tr>
<tr>
<td></td>
<td></td>
<td>GB 2203147 A ,B</td>
</tr>
<tr>
<td></td>
<td></td>
<td>JP 6037450 B</td>
</tr>
<tr>
<td></td>
<td></td>
<td>JP 64000059 A</td>
</tr>
<tr>
<td></td>
<td></td>
<td>LV 11727 B</td>
</tr>
<tr>
<td></td>
<td></td>
<td>WO 9706795 A1</td>
</tr>
<tr>
<td></td>
<td></td>
<td>CH 642060 A5</td>
</tr>
<tr>
<td></td>
<td></td>
<td>DE 2953334 C1</td>
</tr>
<tr>
<td></td>
<td></td>
<td>DE 2953334 T0</td>
</tr>
<tr>
<td></td>
<td></td>
<td>GB 2057432 A ,B</td>
</tr>
<tr>
<td></td>
<td></td>
<td>JP 59018387 B</td>
</tr>
<tr>
<td></td>
<td></td>
<td>JP 55501056 T</td>
</tr>
<tr>
<td></td>
<td></td>
<td>WO 8001068 A1</td>
</tr>
<tr>
<td>SU 978808 A1</td>
<td>07-12-1982</td>
<td>NONE</td>
</tr>
</tbody>
</table>